Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
172results about How to "Reduce tumor volume" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cationic lipids and uses thereof
InactiveUS20090285881A1Reduce tumor volumeBiocideFatty acid chemical modificationLipid formationDisease
Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.
Owner:ABBOTT LAB INC
Compositions and methods for tumor-targeted delivery of effector molecules
InactiveUS20040229338A1Reduce Toxicity RiskReduce riskHeavy metal active ingredientsBiocideTumor targetBacilli
The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
Owner:NANOTHERAPEUTICS INC
Antibodies that bind human cd27 and uses thereof
InactiveUS20120213771A1Enhance immune responseInduce expressionAnimal cellsBacteriaMonoclonal antibodyDiagnostic methods
Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
Owner:CELLDEX THERAPEUTICS INC
Cationic lipids and uses thereof
Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.
Owner:ABBOTT LAB INC
Compositions and methods for tumor-targeted delivery of effector molecules
InactiveUS6962696B1Inhibit tumor growthReduce tumor volumeOrganic active ingredientsHeavy metal active ingredientsTumor targetMelanoma
Owner:NANOTHERAPEUTICS INC
Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
InactiveUS20070298012A1Reduce Toxicity RiskReduce riskHeavy metal active ingredientsBiocideParanasal Sinus CarcinomaMelanoma
The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
Owner:NANOTHERAPEUTICS INC
Compositions and methods for tumor-targeted delivery of effector molecules
InactiveUS20050249706A1Inhibit tumor growthReduce tumor volumeBiocideOrganic active ingredientsTumor targetAbnormal tissue growth
Owner:NANOTHERAPEUTICS INC
Cationic Lipids and Uses Thereof
InactiveUS20100076055A1Reduce tumor volumeOrganic active ingredientsOrganic chemistryDiseaseLipid formation
Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.
Owner:ABBOTT LAB INC
Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof
InactiveUS6762174B1Remarkable effectLow toxicityBiocidePeptide/protein ingredientsVaccinationAnticarcinogen
The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same to stimulate cells of the immune system, bone marrow and other organs. The present compounds can be used to enhance vaccination, increase synthesis of and enhance function of blood cell components and enhance anti-neoplastic effects of various agents. The compounds of the invention can be used to produce a variety of further pharmacologic effects.
Owner:DOVETAIL TECH
Non-covalent inhibitors of urokinase and blood vessel formation
InactiveUS6586405B2Promote cell adhesionImprove cell adhesionTripeptide ingredientsDepsipeptidesBiochemistryIn vivo
Owner:KEVIN S HELMBACHER GENERAL COUNSEL +1
Non-covalent inhibitors of urokinase and blood vessel formation
InactiveUS20020037857A1Promote cell adhesionImprove cell adhesionDipeptide ingredientsDepsipeptidesUrokinase Plasminogen ActivatorIn vivo
Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have Pi a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
Owner:KEVIN S HELMBACHER GENERAL COUNSEL +1
Methods for treating cancer using GRM8 inhibitors
ActiveUS10683352B1Decreasing number and activityReduce tumor volumeOrganic active ingredientsPeptide/protein ingredientsAntiendomysial antibodiesOncology
The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.
Owner:FLAGSHIP PIONEERING INNOVATIONS V INC
Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies
InactiveUS20090214541A1Good curative effectPrevent dimerizationAntibody ingredientsImmunoglobulinsEGFR AntibodyAnti her2
The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Compounds and methods for treatment of cancer
ActiveUS8530404B2Altering activity of tumorReduce tumor volumeBiocidePeptide/protein ingredientsCancer preventionLymphatic Spread
Owner:FIBROGEN INC
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
ActiveUS20160324878A1Good synergyShorten treatment cycleNervous disorderOrganic chemistryDiseaseAutoimmune disease
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.
Owner:ZHEJIANG DTRM BIOPHARMA
Chemoradiotherapy with TS-1/camptothecins
InactiveUS20070036717A1Improve the level ofLess side effectsBiocideIn-vivo radioactive preparationsAbnormal tissue growthSide effect
An antitumor agent for chemoradiotherapy of rectal cancer comprising a combination of TS-1 (a combination drug of tegafur, gimeracil, and oteracil potassium at a 1:0.4:1 molar ratio) and CPT-11 (irinotecan hydrochloride). The antitumor agent of the invention can achieve marked tumor volume reduction without causing major side effects, especially by coadministering it with preoperative radiation therapy. The volume of even large tumors that are refractory to surgical resection can be reduced by coadministering the antitumor agent of the invention with preoperative radiation therapy, making the subsequent surgical resection of the tumor easier.
Owner:THE KITASATO INST
Inhibitors of urokinase and blood vessel formation
InactiveUS6432922B1Positive maintenanceInhibition effectSenses disorderAntipyreticPLG - PlasminogenArginine
Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
Owner:DENDREON PHARMA INC
Use of eribulin and lenvatinib as combination therapy for treatment of cancer
ActiveUS20150005343A1Reduce in quantityPrevent and delay occurrenceBiocideAnimal repellantsLenvatinibEribulin
The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.
Owner:EISIA R&D MANAGEMENT CO LTD
Multifunctional near infrared fluorescent probe and preparation method and application thereof
ActiveCN106929003AStrong penetrating powerLess sample damageOrganic chemistryPhotodynamic therapyPhotodynamic therapyChemical structure
The invention provides a multifunctional near infrared fluorescent probe. The chemical formula of the multifunctional near infrared fluorescent probe is as shown in formula (I), wherein X<1> is -S- or -Se-, R' is C1-12 alkylene, X<2> is -C(CH3)2-, -O- or -Se-, each of R1 and R2 is independently selected from H atoms, C1-18 alkyl or groups as shown in SO3R9, R9 is C1-18 alkyl or benzyl, each R3 and R4 is independently selected from C1-18 alkyl or benzyl, each of R5, R6, R7 and R8 is independently selected from C1-18 alkyl or C1-18 alkyl containing at least one of F, Cl, Br, I, O and S, and each of Y1 and Y2 is independently selected from F, Cl, Br or I. The multifunctional near infrared fluorescent probe can simultaneously detect pH and mercaptan, is a double-response ratio type near infrared fluorescent probe and can be used for the photodynamic therapy of tumors. The invention further provides a preparation method and application of the probe.
Owner:SHENZHEN INST OF ADVANCED TECH
Peritumoral and intratumoral materials for cancer therapy
PendingUS20180021253A1Reduce tumor volumeProlong progression-free survivalOrganic active ingredientsPeptide/protein ingredientsSpecific immunityNeoplasm
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Novel approach for treatment of cancer using immunomodulation
ActiveUS20170266280A1Promote migrationStrong additive/synergisticPeptide/protein ingredientsBoron compound active ingredientsImmunomodulationsNeoplasm
The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8 / 9 in combination with an immune checkpoint inhibitor. The method specifically discloses use of Talabostat in combination with an immune checkpoint inhibitor, its pharmaceutical composition and process of preparing such composition.
Owner:ONKOSXCEL THERAPEUTICS LLC
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
ActiveUS9717745B2Good synergyOvercome recurrenceNervous disorderOrganic chemistryAutoimmune conditionAutoimmune disease
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.
Owner:ZHEJIANG DTRM BIOPHARMA
Dosing regimens for treatment of cea-expressing cancers
InactiveUS20140242081A1Facilitated releaseReduce tumor volumeImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsRegimenCancer research
The present disclosure provides compositions and methods for treating CEA-expressing cancers. Methods for dosing a patient with an antibody that binds to CEA and human CD3 are also provided.
Owner:AMGEN RES (MUNICH) GMBH +1
Methods for treating neoplasia
InactiveUS20150216937A1Improve survivalReduce the burden onHeavy metal active ingredientsOrganic active ingredientsBladder cancerPathology
The invention provides methods of treating neoplasia, for example bladder cancer, by administering an IL-2 fusion protein and one or more therapeutic agents, where the IL-2 fusion protein does not necessarily have to target the neoplasia.
Owner:ALTOR BIOSCI LLC
Therapeutic agent for breast cancer
PendingUS20180303817A1Reduce tumor volumeOrganic active ingredientsAntineoplastic agentsMethyl-1H-indoleMethyl group
The present application discloses a therapeutic agent for breast cancer, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
Owner:EISIA R&D MANAGEMENT CO LTD
TPGS modified docetaxel liposome nano-drug delivery system and preparation method thereof, and application thereof
InactiveCN109224084AReduce systemic toxicityImprove solubilityOrganic active ingredientsPharmaceutical non-active ingredientsZeta potentialCholesterol
The invention relates to a TPGS modified docetaxel liposome nano-drug delivery system, a preparation method and an application thereof. The TPGS modified docetaxel liposome nano-drug delivery system uses phospholipid and cholesterol as membrane materials, Surfactant TPGS modified liposomes and docetaxel (DTX) as anticancer drug were prepared by membrane dispersion ethanol injection ultrasonic dispersion reverse evaporation and freeze drying. The particle size of nano-doxetaxel liposomes modified by TPGS is 80-200 nm, the zeta potential is 0+30 mV or 0-30 mV, the encapsulation efficiency is 75-99%, with a drug loading of 3-15%. The in vitro cell experiment and in vivo pharmacodynamic experiment of the TPGS modified docetaxel liposome nano-drug delivery system prepared by the invention showthat the nano-drug delivery system can inhibit P. Overexpression of gp, decrease of drug efflux, increase of drug enrichment in tumor cells, increase of cytotoxicity and apoptosis rate, increase of tumor therapeutic effect and reversal of multidrug resistance.
Owner:NINGXIA MEDICAL UNIV
Methods and compositions for contributing to the treatment of cancers
ActiveUS8026216B2Selectively-increasing the uptake of anticancer agentsReduce tumor volumeHeavy metal active ingredientsOrganic active ingredientsCisplatinAgonist
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS +1
Methods for treatment of non-small cell lung cancer
ActiveUS8575191B2Shrink tumorReduce the burden onBiocideAntibody ingredientsTyrosine-kinase inhibitorPyrrole
The present invention provides methods of treating non-small cell lung cancer by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound in combination with a therapeutically effective amount of an epidermal growth factor tyrosine kinase inhibitor.
Owner:ARQULE INC
Methods and compositions for treating cancer using serotonin receptor inhibitors
ActiveUS11034751B1Reduces expression and activityReduce tumor volumePeptide/protein ingredientsReceptors for cytokines/lymphoines/interferonsAntiendomysial antibodiesTryptamine Receptors
The present invention provides methods for treating cancer using serotonin receptor inhibitors, such as serotonin receptor inhibitory antibodies, among others. The invention also features compositions containing serotonin receptor inhibitors, methods of diagnosing patients with serotonin receptor-associated cancer, and methods of predicting the response of cancer in a subject to treatment with serotonin receptor inhibitors.
Owner:FLAGSHIP PIONEERING INNOVATIONS V INC
7-ethyl-10-hydroxycamptothecine-polymer conjugated drug and preparation method of drug nano-preparation
ActiveCN106620714ASlow balanced releaseReduce inactivationOrganic active ingredientsPowder deliverySolubilityPermeation
The invention discloses a 7-ethyl-10-hydroxycamptothecine (SN38) conjugated polymer, a preparation method, a nano-preparation of the conjugated polymer and an anti-tumor application. C-10 position or C-20 position hydroxy of a 7-ethyl-10-hydroxycamptothecine compound is conjugated with different molecular weight terminal carboxyl group polymers through covalent bonds to obtain an SN38 series conjugated prodrug, and then amphiphilic polymer materials and the SN38 prodrug are prepared into a nano-drug. The nano-drug solves the problem of poor water solubility of SN38, and slow release of the SN38 is achieved in vitro. Besides, the particle diameter of the nano-drug is mainly distributed within the range of 20-50nm, high permeability and EPR (enhanced permeation and retention) effects of nano-particles through solid tumors are achieved, and passive targeting functions of the nano-particles are enhanced. The nano-drug has good effects in vitro and vivo and accordingly has a good application prospect.
Owner:ZHEJIANG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com